Shire Agrees to Acquisition by Takeda Pharmaceutical
Wednesday, May 9 2018 | 18 h 00 min | News
Takeda Pharmaceutical Company and Shire announced on Tuesday May 8 that they have reached agreement for Takeda to acquire Shire for $80.5 billion CAD.
Under the terms of the acquisition, each Shire shareholder will be entitled to receive $39.43 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.
The transaction has been approved by both companies’ boards of directors, and is expected to close in the first half of calendar year 2019.
Upon the closing of the transaction, Takeda shareholders will own approximately 50 percent of the combined group.
“Since its inception, Takeda has transformed into an agile, R&D-driven global pharmaceutical company that is well-positioned to deliver innovative and transformative care to patients around the world,” said Christophe Weber, president and chief executive officer of Takeda. “Shire’s highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda. Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies. We are looking forward to the benefits this combination will bring to patients worldwide, the opportunities it will bring for our employees and the returns it will deliver for our shareholders.”
Read the complete Press Release HERE.
